摘要
目的评价无抽搐电休克治疗精神分裂症患者激越、攻击、破坏行为的临床效果及安全性。方法将60例具有激越、攻击、破坏行为的精神分裂症患者随机分为两组，每组30例，研究组常规进行无抽搐电休克治疗，对照组肌肉注射氟哌啶醇治疗，观察14d。于治疗前及治疗1d、3d、7d、9d、14d末采用阳性与阴性症状量表、临床总体印象量表、副反应量表评定临床疗效及不良反应。结果治疗后两组阳性与阴性症状量表总分、阳性症状分、兴奋症状分、临床大体印象量表总分均较治疗前有显著下降（P〈0．05或0．01）；同期研究组均较对照组下降显著（P〈0．05或0．01），副反应量表评分显著低于对照组（P〈0．05）。结论无抽搐电休克治疗精神分裂症激越行为起效快、疗效显著、不良反应轻微、安全性高。
Objective To evaluate clinical efficacy and safety of MECT in the treatment of agitated, agressire and disruptive behavior of schizophrenia. Methods 60 schizophrenics with agitated, agressive and disruptive behavior were randomly assigned to two groups of 30 patients each, research group received routine MECT and control did intramscular injection of haloperidol for 14 days. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and Clinical Global Impression（CGI） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of day 1, 3, 7, 9, 14 treatment. Results After treatment, total, postive and negative symptom scores of the PANSS and total scores of the CGI of both groups lowered more significantly compared pretreatment（P〈0.05 or 0.01） ; those did more significantly in the research than in the control group in the corresponding time period（P〈0.05 or 0.01）. TESS scores were significantly lower in the research than in the control group （P〈0.05）. Conclusion MECT takes effects quick and has an evident effect, mild adverse reactions and high safety in the treatment of agitated behavior of schizophrenia.
出处
《临床心身疾病杂志》
CAS
2009年第6期488-489,共2页
Journal of Clinical Psychosomatic Diseases
